FDA Safety Announcement: Asthma Drug Xolair Increases Risk of Heart and Brain Blood Vessel Problems in Children and Adults

Xolair is a dangerous prescription medication manufactured by Genentech, and intended to treat allergy related asthma in patients 12 years old to adulthood. On September 26, the FDA issued a safety announcement advising that it is making changes to the Xolair label to warn of heart and brain blood vessel problems it causes, including pulmonary hypertension, pulmonary embolism, stroke and heart attack. The FDA’s warning is the result of a 5 year safety study commenced in 2009 after these risks became known to the FDA. Here is a link to the FDA’s Safety Announcement: http://www.fda.gov/Drugs/DrugSafety/ucm414911.htm

From my perspective, FDA and Genentech could have prevented a lot of serious injuries had the warning been issued earlier, because most physicians would find that the life-threatening risks of Xolair outweigh the benefits of the drug.

If you or a loved one suffered from pulmonary hypertension, a pulmonary embolism, stroke or heart attack, please feel free to contact the Levensten Law Firm at www.levenstenlawfirm.com or 215-545-5600 to learn how to protect your rights to compensation. Additional information may also be found at our Xolair website, www.xolairlawyers.com.